IBio Income After Taxes 2010-2024 | IBIO

IBio income after taxes from 2010 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.

IBio Income After Taxes 2010-2024 | IBIO

IBio income after taxes from 2010 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$159.1B
Vertex Pharmaceuticals (VRTX)$124.6B
Bristol Myers Squibb (BMY)$118.6B
Gilead Sciences (GILD)$114.8B
CSL (CSLLY)$88.8B
Regeneron Pharmaceuticals (REGN)$86B
GSK (GSK)$71.3B
Argenex SE (ARGX)$35.6B
Alnylam Pharmaceuticals (ALNY)$33.3B
BioNTech SE (BNTX)$24.8B
Biogen (BIIB)$24B
Illumina (ILMN)$22.6B
BeiGene (BGNE)$18.8B
Moderna (MRNA)$15.3B
Incyte (INCY)$15B
Genmab (GMAB)$14B
Insmed (INSM)$12.7B
BioMarin Pharmaceutical (BMRN)$12.5B
Vaxcyte (PCVX)$11.6B
Bio-Techne Corp (TECH)$11.5B
Sarepta Therapeutics (SRPT)$10.4B
Exelixis (EXEL)$10B
Revolution Medicines (RVMD)$9.7B
QIAGEN (QGEN)$9.6B
Exact Sciences (EXAS)$9.4B
Bio-Rad Laboratories (BIO.B)$9.4B
Intra-Cellular Therapies (ITCI)$9.3B
Roivant Sciences (ROIV)$8.6B
Repligen (RGEN)$8B
Ascendis Pharma (ASND)$7.5B